Kinetics of intrahepatic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B: Lessons from experimental and clinical studies

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 8, 2013, Pages 1011-1013

  Zoulim, Fabien ^a   Testoni, Barbara ^a   Lebossé, Fanny ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; AMINOTRANSFERASE; CIRCULAR DNA; CLEVUDINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TELBIVUDINE; VIRUS DNA;

AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; CHRONIC HEPATITIS; EDITORIAL; HEPATITIS B; HEPATITIS B VIRUS; KINETICS; LONG TERM CARE; NONHUMAN;

ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; LIVER; MALE; NUCLEOSIDES; NUCLEOTIDES;

EID: 84880604892     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.04.010     Document Type: Editorial

References (24)

1. Gish R., Jia J.D., Locarnini S., et al. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis 2012, 12:341-353.
2. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-185. European Association for the Study of the Liver.
3. Chang T.T., Liaw Y.F., Wu S.S., et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010, 52:886-893.
4. Marcellin P., Gane E., Buti M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013, 381:468-475.
5. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005, 42:302-308.
6. Simonetti J., Bulkow L., McMahon B.J., et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010, 51:1531-1537.
7. Yuen M.F., Wong D.K., Fung J., et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008, 135:1192-1199.
8. Wong D.K.-H., Seto W.-K., Fung J., et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol 2013, 11:1004-1010.
9. Levrero M., Pollicino T., Petersen J., et al. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009, 51:581-592.
10. Delmas J., Schorr O., Jamard C., et al. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother 2002, 46:425-433.
11. Zhu Y., Yamamoto T., Cullen J., et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001, 75:311-322.
12. Le Guerhier F., Pichoud C., Guerret S., et al. Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrob Agents Chemother 2000, 44:111-122.
13. Le Guerhier F., Pichoud C., Jamard C., et al. Antiviral activity of beta-L-2,3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Antimicrob Agents Chemother 2001, 45:1065-1077.
14. Moraleda G., Saputelli J., Aldrich C.E., et al. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997, 71:9392-9399.
15. Janssen H.L., Sonneveld M.J., Brunetto M.R. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?. Gut 2012, 61:641-645.
16. Werle-Lapostolle B., Bowden S., Locarnini S., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004, 126:1750-1758.
17. Sung J.J., Wong M.L., Bowden S., et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005, 128:1890-1897.
18. Lacombe K., Boyd A., Lavocat F., et al. High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among HIV-hepatitis B infected patients. Hepatology 2013 Mar 6, Epub ahead of print.
19. Wursthorn K., Lutgehetmann M., Dandri M., et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006, 44:675-684.
20. Belloni L., Allweiss L., Guerrieri F., et al. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012, 122:529-537.
21. Chevaliez S., Hézode C., Bahrami S., et al. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 2013, 58:676-683.
22. Borgniet O., Parvaz P., Bouix C., et al. Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. J Med Virol 2009, 81:1336-1342.
23. Thompson A.J., Nguyen T., Iser D., et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010, 51:1933-1944.
24. Zoulim F. Are novel combination therapies needed for chronic hepatitis B?. Antiviral Res 2012, 96:256-259.